Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
Which drugs does patent 8,338,486 protect, and when does it expire?
| Title: | Methods for the treatment of CNS-related conditions |
| Abstract: | The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. |
| Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV) |
| Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
| Application Number: | 13/536,763 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | ► Subscribe | ► Subscribe | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||||||||||||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | AB | RX | Yes | No | ► Subscribe | ► Subscribe | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | |||||||||||||||||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | RX | Yes | No | ► Subscribe | ► Subscribe | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||||||||||||
Forest Labs Llc | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,362,085 | Method for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||||||||||||||||
| 8,426,472 | Method and composition for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||||||||||||||||
| 2,012,045,508 | ► Subscribe | ||||||||||||||||||||||||||||
| 8,168,209 | Method and composition for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||||||||||||||||
| 8,058,291 | Methods and compositions for the treatment of CNS-related conditions | ► Subscribe | |||||||||||||||||||||||||||
| 8,580,858 | Compositions for the treatment of CNS-related conditions | ► Subscribe | |||||||||||||||||||||||||||
| 7,619,007 | Method and composition for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||||||||||||||||
| 8,338,485 | Compositions for the treatment of CNS-related conditions | ► Subscribe | |||||||||||||||||||||||||||
| 8,293,794 | Methods and compositions for the treatment of CNS-related conditions | ► Subscribe | |||||||||||||||||||||||||||
| 8,329,752 | Composition for administering an NMDA receptor antagonist to a subject | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 481096 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2005209310 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2005215767 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2005215775 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2005309601 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2006244297 | ► Subscribe | |||||||||||||||||||||||||||
| Brazil | PI0518483 | ► Subscribe | |||||||||||||||||||||||||||
| Brazil | PI0607017 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2554959 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2556214 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,720 others who get our Drug Patent Expiration Alerts:
